Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 38: Death Pathways, DNA Repair, and Drug Delivery

Small molecule inhibitors of DNA-PKcs and ATM inhibit DNA repair and sensitize cells to ionizing radiation

Ian G. Cowell, Barbara W. Durkacz and Michael J. Tilby
Ian G. Cowell
Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara W. Durkacz
Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Tilby
Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

4391

ATM and DNA-PKcs are members of the phosphatidylinositol (PI) 3-kinase like kinase (PIKK) family of serine/threonine protein kinases. While ATM is a key regulator of the cellular response to ionising radiation and other DNA double strand break inducing treatments, DNA-PK is essential for efficient DNA repair by non homologous end joining (NHEJ). The Northern Institute for Cancer Research, in collaboration with KuDOS Pharmaceuticals, has synthesised and evaluated a series of novel DNA-PK and ATM inhibitors. These include NU7441 (Griffin et al, Proc Amer Assoc Cancer Res, 45:4362, 2004) and KU-55933 (Hickson et al Cancer Res, in press), potent and specific inhibitors of DNA-PK and ATM kinase activities respectively. We demonstrate that both drugs sensitize MCF7 breast carcinoma cells to ionizing radiation. Since DNA-PK is required for efficient NHEJ, inhibition of DNA repair is the expected mechanism for NU7441-induced radiosensitization. We have confirmed this by analyzing radiation induced phosphorylation of histone H2AX in the presence or absence of the inhibitors. The histone variant H2AX is phosphorylated over large chromatin domains at sites of DNA DSBs to form γH2AX foci that are visible by immunofluorescence microscopy. We observed a significant delay in the disappearance of IR-induced γH2AX foci in NU7441 treated MCF7 cells compared to cells irradiated in the absence of drug. Similarly, IR-induced foci were slower to disappear in KU-55933 treated cells, but in this case the γH2AX fluorescence signal was initially weaker than in untreated cells. This is consistent with the reported role of ATM in IR induced phosphorylation of H2AX. Notably, inhibition of DNA-PK had only a small effect on the initial phosphorylation of H2AX but simultaneous treatment with both compounds dramatically reduced initial γH2AX focus formation (15 min after IR). However, γH2AX foci did appear at later times, indicating that another PIKK family member, probably ATR, is able to phosphorylate H2AX to some degree after irradiation. We also observed in most cells an increase in fluorescence intensity from those foci that were remaining after 24 hours, suggesting time dependent increase in the number of phosphorylated H2AX molecules at sites of DSBs. We hypothesise that these novel inhibitors will specifically radio- and chemosensitize breast carcinomas that harbour existing DNA DSB repair defects. With this in mind we intend to compare the radio- and chemosensitizing potential of these drugs in breast carcinoma cell lines harbouring or engineered to contain different DNA damage response deficiencies.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Small molecule inhibitors of DNA-PKcs and ATM inhibit DNA repair and sensitize cells to ionizing radiation
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Small molecule inhibitors of DNA-PKcs and ATM inhibit DNA repair and sensitize cells to ionizing radiation
Ian G. Cowell, Barbara W. Durkacz and Michael J. Tilby
Cancer Res May 1 2005 (65) (9 Supplement) 1039;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Small molecule inhibitors of DNA-PKcs and ATM inhibit DNA repair and sensitize cells to ionizing radiation
Ian G. Cowell, Barbara W. Durkacz and Michael J. Tilby
Cancer Res May 1 2005 (65) (9 Supplement) 1039;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • HGS-TR2J, an agonistic, TRAIL receptor 2 monoclonal antibody, actively and rapidly stimulates the TRAIL receptor pathway that leads to significant inhibition of tumor growth in human tumor cell lines in vitro and in vivo
  • Targeting stathmin, a p53-regulated protein, sensitizes human breast cancer cells to antimicrotubule drugs
  • Novel Ep-CAM specific liposomal drug delivery systems for targeted therapy of solid tumors
Show more Experimental and Molecular Therapeutics 38: Death Pathways, DNA Repair, and Drug Delivery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement